Faricimab meets primary endpoint in phase 3 studies for diabetic macular edema
Faricimab met its primary endpoint in 2 phase 3 studies for the treatment of diabetic macular edema (DME), according to a press release.
In the YOSEMITE and RHINE studies, faricimab (Genentech) demonstrated non-inferior visual acuity gains when given every 8 weeks and at personalized dosing intervals of up to 16 weeks compared to aflibercept given every 8 weeks. Treatment was generally well-tolerated.
In patients receiving faricimab at personalized dosing intervals, more than half achieved an extended time between treatments of 16 weeks at year one.
“These positive results show that faricimab has the potential to offer lasting vision improvements for people with diabetic macular edema, while also reducing the treatment burden associated with frequent eye injections,” said Levi Garraway, MD, PhD, chief medical officer and head of Global Product Development, in the press release. “We look forward to discussions with global regulatory authorities, with the aim of bringing this potential new treatment option to people with this condition as soon as possible.”
Read the full press release here.
